Clinical trials · New York, NY
Non Muscle Invasive Bladder Cancer clinical trials in New York
We’re tracking 28 recruiting non muscle invasive bladder cancer studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT02660645Recruiting
Blue light bladder scan for suspected bladder cancer
This trial uses a special blue-light camera during a bladder procedure to help doctors better see non-muscle-invasive bladder cancer. It may help find cancer spots more clearly so they can be treated sooner.
New York, New YorkAges 18 years+ - NCT06833073RecruitingPhase 2
Study of an mRNA vaccine and BCG for bladder cancer
This trial tests an experimental mRNA vaccine (V940) combined with BCG therapy for people with high-risk non-muscle invasive bladder cancer that hasn't spread. It aims to see if the vaccine can help the immune system better fight the cancer.
New York, New YorkAges 18 years+ - NCT06510374RecruitingPhase 3
Gene therapy vs. observation for intermediate risk bladder cancer
This trial tests a new gene therapy called nadofaragene firadenovec versus just watching and waiting (observation) for people with a specific type of bladder cancer that hasn't grown into the muscle. The goal is to see if the gene therapy can help keep the cancer from coming back.
New York, New YorkAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
New York, New YorkAges 18 years+ - NCT07206225RecruitingPhase 1
Study of PF-08052667 in non-muscle invasive bladder cancer
This trial tests a new study medicine called PF-08052667 for people with a certain type of bladder cancer that hasn't spread into the muscle. It's for those who have already tried BCG treatment and can't or won't have their bladder removed.
New York, New YorkAges 18 years+ - NCT06929286RecruitingPhase 3
Comparing treatments for non-invasive bladder cancer
This trial tests if a new gene therapy, nadofaragene firadenovec, works better than standard treatments for people with high-risk bladder cancer that hasn't spread into the muscle layer. You may qualify if BCG therapy has stopped working and you need another option.
New York, New YorkAges 21 years+ - NCT04752722RecruitingPhase 1/Phase 2
Gene therapy for bladder cancer that came back after BCG
This study tests a new gene therapy (EG-70) given directly into the bladder for people with a high-risk bladder cancer called NMIBC. It may be an option if BCG treatment stopped working, or if you cannot have or choose not to have bladder removal surgery.
New York, New YorkAges 18 years+ - NCT06545955RecruitingPhase 3
Gene therapy study for high-grade bladder cancer not responding to BCG
This trial tests a gene therapy called nadofaragene firadenovec, given directly into the bladder, either alone or with chemo or immunotherapy. It's for people with high-grade bladder cancer that hasn't gone away after BCG treatment.
New York, New YorkAges 18 years+ - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
New York, New YorkAges 40–75 - NCT07000084RecruitingPhase 3
Testing gemcitabine with BCG for returning bladder cancer
This trial tests whether adding a chemotherapy drug called gemcitabine to the usual BCG therapy can help prevent bladder cancer from coming back again. If you have had BCG before and your cancer returned, this study might offer a more effective treatment option.
New York, New YorkAges 18 years+ - NCT06567743RecruitingPhase 2
Study of a new virus therapy for high-risk bladder cancer
This trial tests a new virus-based medicine, cretostimogene grenadenorepvec, given directly into the bladder for people with high-risk non-muscle-invasive bladder cancer. It may help prevent the cancer from coming back, especially for those who have not had BCG treatment or whose cancer did not respond to BCG.
New York, New YorkAges 18 years+ - NCT05951179RecruitingPhase 2
Bladder instillation study for high-grade non–muscle-invasive cancer
This Phase 2 trial tests TARA-002 given directly into the bladder to treat high-grade non–muscle-invasive bladder cancer with active disease. It may help patients who have not previously responded to, or have not received, BCG treatment in the recent past.
New York, New YorkAges 18 years+ - NCT06319820RecruitingPhase 3
TAR-210 vs standard bladder chemo for FGFR-mutated bladder cancer
This trial compares a new drug, TAR-210, which is placed directly into the bladder, against standard chemotherapy given through a catheter. It is for people with a specific type of bladder cancer that has a change in the FGFR gene.
New York, New YorkAges 18 years+ - NCT07720284RecruitingPhase 3
Testing new drugs for high-risk bladder cancer after surgery
This trial tests a new combination of drugs (Dato-DXd plus rilvegostomig) against standard treatments for people with high-risk, muscle-invasive bladder cancer that has been surgically removed. The goal is to see if the new treatment reduces the chance of the cancer coming back.
New York, New YorkAges 18 years+ - NCT06571708RecruitingPhase 2
Chemo plus immunotherapy for muscle-invasive bladder cancer
This trial tests adding two immunotherapy drugs (cemiplimab and fianlimab) to standard chemotherapy (gemcitabine and cisplatin) for people with bladder cancer that has grown into the muscle layer but hasn't spread. The goal is to see if adding these immunotherapies helps shrink the tumor before surgery.
New York, New YorkAges 18 years+ - NCT06503614RecruitingPhase 2
Durvalumab and monalizumab for early bladder cancer
This trial tests two drugs—durvalumab and monalizumab—for people with early-stage bladder cancer that hasn't spread into the muscle and has persisted or returned after BCG treatment. The goal is to see if this combination can control the cancer and delay or avoid the need for bladder removal surgery.
New York, New YorkAges 18 years+ - NCT05126472RecruitingPhase 1/Phase 2
Study of 2141-V11 for bladder cancer that did not respond to standard treatment
This trial tests a new drug, 2141-V11, for people with bladder cancer that has not gone away after standard treatments like BCG therapy. It may help those with non-muscle invasive bladder cancer or, in one group, muscle-invasive bladder cancer, who cannot have or choose not to have bladder removal surgery.
New York, New YorkAges 18 years+ - NCT05239624RecruitingPhase 2
Enfortumab plus pembrolizumab for muscle-invasive bladder cancer
This Phase 2 study tests how well two anti-cancer medicines—enfortumab vedotin and pembrolizumab—work for people with muscle-invasive bladder cancer that has spread to nearby lymph nodes (but not distant organs). It may help shrink the cancer and improve treatment outcomes before or around planning major surgery.
New York, New YorkAges 18 years+ - NCT06770582RecruitingPhase 2
Adding immunotherapy to radiation for bladder cancer
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
New York, New YorkAges 18 years+ - NCT06995677RecruitingPhase 2
TYRA-300 pill for low-grade bladder cancer with FGFR3 change
This study tests an experimental pill called TYRA-300 for people with low-grade bladder cancer that hasn't spread into the muscle layer. The pill targets a specific gene change (FGFR3) found in the tumor. The goal is to see if it can slow or shrink the cancer.
New York, New YorkAges 18 years+ - NCT07673016Recruiting
Collecting urine to test a new bladder cancer detection method
This study collects urine samples to test UroAmp, a new genetic test that may help detect and monitor bladder cancer. It is for people with bladder cancer or blood in urine who want to help improve cancer detection.
New York, New YorkAges 18 years+ - NCT07475806RecruitingPhase 2
Bladder-sparing drug combo for muscle-invasive bladder cancer
This study tests two drugs, enfortumab vedotin and pembrolizumab, to see if they can help people with muscle-invasive bladder cancer avoid removing their bladder. The drugs are given before the standard surgery to possibly shrink the tumor and improve outcomes.
New York, New YorkAges 18 years+ - NCT07061964RecruitingPhase 2
Immunotherapy and radiation to save the bladder
This trial tests whether combining immunotherapy and low-dose radiation after chemotherapy can help you avoid bladder removal. It's for people whose muscle-invasive bladder cancer has shrunk significantly after initial treatment.
New York, New YorkAges 18 years+ - NCT05059444Recruiting
Blood test study to watch for cancer coming back
This study looks at whether blood tests can detect signs that cancer may return after curative-intent treatment. You would have blood drawn around your usual follow-up visits for up to 5 years, and your de-identified health data would be shared with study investigators.
New York, New YorkAges 18 years+
Hear when a new Non Muscle Invasive Bladder Cancer trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Non Muscle Invasive Bladder Cancer trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting non muscle invasive bladder cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 9 studies
- Memorial Sloan Kettering Bergen · 6 studies
- Memorial Sloan Kettering Monmouth · 6 studies
- Memorial Sloan Kettering Nassau · 6 studies
- Memorial Sloan Kettering Basking Ridge · 5 studies
- Memorial Sloan Kettering Westchester · 5 studies
- Memorial Sloan Kettering Commack · 4 studies
- NYU Langone Health · 4 studies
What taking part in a non muscle invasive bladder cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting non muscle invasive bladder cancer studies in New York.
Common questions
- Are there non muscle invasive bladder cancer clinical trials near New York?
- Yes. We're currently tracking 28 recruiting non muscle invasive bladder cancer studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a non muscle invasive bladder cancer study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a non muscle invasive bladder cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New non muscle invasive bladder cancer studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.